Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04518748 · ClinicalTrials.gov registry record · Phase 1
Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.
A Phase 1 study of Liver Malignancy, sponsored by University of Michigan Rogel Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT04518748 is a Phase 1 study of Liver Malignancy that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 70 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04518748, a Phase 1 study of Liver Malignancy, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will investigate the combination of Ytrium-90 (Y-90) Selective Internal Radiation Therapy (SIRT) followed by Stereotactic Body Radiation Therapy (SBRT). Y-90 SIRT alone or SBRT alone are standard procedures used in the treatment of liver cancer. This study will assess the combination of Y-90 SIRT and SBRT and obtain preliminary information about the side effects and safety of the combination therapy. Additionally, this is the first time that Y-90 PET-CT imaging will be included in planning for SBRT.
Conditions Studied
Interventions
- RADIATION Stereotactic Body Radiation Therapy
- DIAGNOSTIC_TEST PET/CT
- DRUG Yttrium-90
- DEVICE Selective Internal Radiation Therapy
- DEVICE Therasphere
Study Locations (1)
Michigan
- University of Michigan Rogel Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2020-09-16 |
| Est. Completion | 2028-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04518748
The ClinicalTrials.gov registry entry for NCT04518748 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Liver Malignancy appearing as the primary indexed condition, and to 5 interventions - of which Stereotactic Body Radiation Therapy is the first listed.
NCT04518748 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT04518748 about?
NCT04518748 is a clinical study titled "Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.". This study will investigate the combination of Ytrium-90 (Y-90) Selective Internal Radiation Therapy (SIRT) followed by Stereotactic Body Radiation Therapy (SBRT). Y-90 SIRT alone or SBRT alone are standard procedures used in the treatment of liver cancer. This study will assess the combination of Y...
What is the current status of trial NCT04518748?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2020-09-16. Estimated completion is 2028-11.
What conditions does trial NCT04518748 study?
This clinical trial studies the following conditions: Liver Malignancy.
What interventions are being tested in trial NCT04518748?
The interventions under investigation include: Stereotactic Body Radiation Therapy (RADIATION), PET/CT (DIAGNOSTIC_TEST), Yttrium-90 (DRUG), Selective Internal Radiation Therapy (DEVICE), Therasphere (DEVICE).
Who is sponsoring clinical trial NCT04518748?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04518748 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.